Subscribe
Search
Close this search box.
Subscribe
Search
Close this search box.

Obulytix is developing a revolutionary solution for antibiotic resistance

Obulytix, a spin-off based on research results from Ghent University and KU Leuven, has built a platform that creates new ways to tackle bacterial infections. The innovative, phage lysin-based platform – leveraging the power of artificial intelligence – attracted a significant four-million-euro investment from Boehringer Ingelheim Venture Fund, Qbic, and Gemma Frisius Fund.

Azalea Vision announces first on-eye test of ALMA, its revolutionary smart contact lens

In a significant milestone, Azalea Vision, pioneering start-up on a mission to revolutionize the treatment of ocular disorders, announces the successful demonstration of ALMA Lens, the first functional prototype of the Azalea smart contact lens’ platform.

Pioneering Belgian project ATHENA paves the way for Real-World Data reuse in research and personalized care

ATHENA, a VLAIO-funded multi-stakeholder project, clears the path for increased reuse of Real-World Data in scientific research and healthcare, by introducing innovative solutions and responding to current technical and governance challenges. The project has made significant strides in the field of oncology by developing groundbreaking privacy-preserving machine learning techniques for predictive analytics. The project findings will be presented and discussed at the ATHENA symposium on November 23rd, 2023.

Belgium – nurturing innovation at the interface of biology and technology

The ´Science for health´ congress gathers local and global experts in Brussels on November 28 to discuss how to adapt healthcare to current challenges, combining cutting-edge technology with biology and place Belgium at the forefront of healthcare innovation.

miDiagnostics announces collaboration with Galapagos to develop closed-flow, ultra-rapid CAR-T sterility test for its point-of-care CAR-T manufacturing platform

V-Bio Ventures portfolio company Agomab raises $100 million Series C to advance fibrosis-focused pipeline

Agomab Therapeutics NV (‘Agomab’) today announced the closing of a $100 million (€94.9 million) Series C financing round led by Fidelity Management & Research Company, with participation from new investors EQT Life Sciences (EQT), Canaan, Dawn Biopharma, a platform controlled by KKR, and existing investors.

V-Bio Ventures portfolio company Orionis Biosciences announces collaboration with Genentech to discover and develop molecular glue class medicines

Augustine Therapeutics expands its leadership team and R&D platform, enters regulatory development.

V-Bio Ventures portfolio company Corteria Pharmaceuticals raises EUR 65 million to advance its transformational medicines for cardiovascular diseases

The QbD Group acquires Turnstone Communications and BioVox to strengthen its specialist science communication and marketing services

V-Bio Ventures portfolio company Dualyx raises €40 million to progress Treg therapies for autoimmune diseases into the clinic

Power to the patient: Conference tackles challenges of medtech innovation

V-Bio Ventures portfolio company Confo Therapeutics Announces Global Licensing Agreement with Lilly for Peripheral Pain Candidate, CFTX-1554

CMT Research Foundation (USA) collaborates with Augustine Therapeutics on new therapy against Charcot-Marie-Tooth disease

MedTech Flanders becomes part of MEDVIA, Flanders’ healthtech spearhead cluster